US FDA Guidance Homes In On RnD Challenges For Rare Disease Drug Makers
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has issued a draft guidance document that seeks to advance and facilitate the development of medicines for preventing and treating rare diseases by discussing issues commonly encountered by orphan drug makers1.
Register for our free email digests: